Vijay Chopra
Overview
Explore the profile of Vijay Chopra including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
3684
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang M, Henderson A, Talebi A, Atherton J, Chiang C, Chopra V, et al.
J Am Coll Cardiol
. 2024 Nov;
85(2):120-136.
PMID: 39520455
Background: Patients with heart failure (HF) are limited by symptoms and have impaired quality of life. The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a patient-reported outcome measure that enables evaluation...
2.
Zieroth S, Giraldo C, Pinto F, Anker S, Abraham W, Atherton J, et al.
Eur J Heart Fail
. 2024 Oct;
PMID: 39453685
Aims: Clinical practice guidelines are commonly written by professional societies in high-income countries (HIC) with limited anticipation of implementation obstacles in other environments. We used heart failure (HF) guidelines as...
3.
Solomon S, McMurray J, Vaduganathan M, Claggett B, Jhund P, Desai A, et al.
N Engl J Med
. 2024 Sep;
391(16):1475-1485.
PMID: 39225278
Background: Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality among patients with heart failure and reduced ejection fraction, but their efficacy in those with heart failure and mildly reduced or...
4.
Solomon S, Ostrominski J, Wang X, Shah S, Borlaug B, Butler J, et al.
J Am Coll Cardiol
. 2024 Sep;
84(17):1587-1602.
PMID: 39217567
Background: Obesity is associated with adverse cardiac remodeling and is a key driver for the development and progression of heart failure (HF). Once-weekly semaglutide (2.4 mg) has been shown to...
5.
Solomon S, Ostrominski J, Vaduganathan M, Claggett B, Jhund P, Desai A, et al.
Eur J Heart Fail
. 2024 May;
26(6):1334-1346.
PMID: 38733212
Aims: To describe the baseline characteristics of participants in the FINEARTS-HF trial, contextualized with prior trials including patients with heart failure (HF) with mildly reduced and preserved ejection fraction (HFmrEF/HFpEF)....
6.
Butler J, Shah S, Petrie M, Borlaug B, Abildstrom S, Davies M, et al.
Lancet
. 2024 Apr;
403(10437):1635-1648.
PMID: 38599221
Background: In the STEP-HFpEF (NCT04788511) and STEP-HFpEF DM (NCT04916470) trials, the GLP-1 receptor agonist semaglutide improved symptoms, physical limitations, bodyweight, and exercise function in people with obesity-related heart failure with...
7.
Kosiborod M, Petrie M, Borlaug B, Butler J, Davies M, Hovingh G, et al.
N Engl J Med
. 2024 Apr;
390(15):1394-1407.
PMID: 38587233
Background: Obesity and type 2 diabetes are prevalent in patients with heart failure with preserved ejection fraction and are characterized by a high symptom burden. No approved therapies specifically target...
8.
Butler J, Abildstrom S, Borlaug B, Davies M, Kitzman D, Petrie M, et al.
J Am Coll Cardiol
. 2023 Nov;
82(22):2087-2096.
PMID: 37993201
Background: Many therapies for heart failure (HF) have shown differential impact across the spectrum of left ventricular ejection fraction (LVEF). Objectives: In this prespecified analysis, the authors assessed the effects...
9.
Jadhav U, Nair T, Mohanan P, Chopra V, Kerkar P, Das Biswas A, et al.
Cureus
. 2023 Oct;
15(9):e45241.
PMID: 37849613
Epidemiological data from the Indian subcontinent on the burden of Heart failure (HF) is scarce. Mineralocorticoid receptor antagonists (MRAs) are usually used in the management of HF and hypertension. A...
10.
Borlaug B, Kitzman D, Davies M, Rasmussen S, Barros E, Butler J, et al.
Nat Med
. 2023 Aug;
29(9):2358-2365.
PMID: 37635157
In the STEP-HFpEF trial, semaglutide improved symptoms, physical limitations and exercise function and reduced body weight in patients with obesity phenotype of heart failure and preserved ejection fraction (HFpEF). This...